Trial Profile
A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer With Tumors Expressing PD-L1 ≥50%
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 21 Nov 2022
Price :
$35
*
At a glance
- Drugs Cemiplimab (Primary) ; Ipilimumab (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Paclitaxel; Pembrolizumab; Pemetrexed
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms EMPOWER-lung 2
- Sponsors Regeneron Pharmaceuticals
- 12 Aug 2021 Status changed from active, no longer recruiting to completed.
- 05 Feb 2021 According to a Regeneron Pharmaceuticals media release, results are expected in 2021.
- 06 Oct 2020 This trial has been completed in Lithuania, according to European Clinical Trials Database record.